Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine followed by buprenorphine for suicidal ideation in MDD
NCT04116528Phase 3Completed
- Sponsor
- Stanford University
- Start
- Aug 2020
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of v1003 in major depressive disorder (MDD) (2 arms), sponsored by Stanford University. Primary endpoint: Scale for Suicidal Ideation Total Score at Day 31. Started Aug 2020; status: completed.
02
Drugs
v1003
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04116528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116528.